References
- Moncada S., Gryglewski R. J., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (London) 1976; 263: 663
- Schillinger E., Krais T., Stock Iloprost G. New drugs annual: Cardiovascular drugs, A. Scriabine. Raven Press, New York 1987; 209–231
- Skuballa W., Vorbrüggen H. Synthesis of iloprost (ZK 36374): A chemically stable and biologically potent prostacyclin analog. Advan. Prostagl. Thromb. and Leukotr. Res. 1983; 11: 299–305
- Casals-Stenzel J., Buse M., Losert W. Comparison of the vasodepressor actions of ZK 36374, a stable prostacyclin derivative, PGl2 and PGE1, with their effect on platelet aggregation. Prostagland. Leukotr. Med 1983; 10: 197
- Darius H., Hossmann V., Auel H., Schrör K. Hemodynamic and platelet effects of iloprost in patients with peripheral arterial disease. Prostaglandins and Other Eicosanoids in the Cardiovascular System, K. Schrör. Karger Verlag, Basel 1985; 292
- Diehm C. Placebo-kontrollierte doppelblinde 13-Center-Studie zum Nachweis der therapeutischen Wirksamkeit von iloprost bei Patienten mit arterieller Verschlulβ-krankheit (Stad. IV). Klin. Wochenschr. 1987; 65: 38
- Fissinger J. N., Schäfer M. Trial of Iloprost vs. Aspirin for critical limb ischemia of thrombangiitis obliterans. Lancet 1990; 335: 555–557
- Krause Krais W. Th. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur. J. Clin. Pharmacol. 1986; 30: 61
- Krause W., Krais Th. Pharmacokinetics and pharmacodynamics of radiolabelled iloprost in elderly volunteers. Eur. J. Clin. Pharmacol. 1987; 32: 597
- Hildebrand M., Krause W., Oberender H. A., Zurdel S., Dillinger Jünger M., Bodenburg H. Pharmacokinetics of iloprost in PAOD-patients. Eicosanoids 1990; 3: 145
- Hildebrand M., Krause W., Angeli P., Wool C., Koziol T., Gatta A., Merkel C. M. Bolognesi Pharmacokinetics of iloprost in patients with hepatic dysfunction. Clin. Pharmacol. Ther. Tox. 1990; 28: 430
- Hildebrand M., McDonald F. M., Windt-Hanke F. Pharmacokinetic characterization of oral sustained release preparations of iloprost in a pig model. Prostaglandins 1991; 41: 473–486
- Hildebrand M., Nieuweboer B., Biere H., Klar U., Seemann G., Krause W., Jakobs U. Development, Validation and Practical Use of A Sensitive and Specific RIA for the Determination of Iloprost. Eicosanoids 1990; 3: 165–169
- Grant S. M., Goa K. L. Iloprost - A review of its pharmacodyamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischemia and extracorporeal circulation procedures. Drugs 1992; 43: 889–924